Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New diabetes drug shows promise for safe ramadan fasting

NCT ID NCT06635057

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether starting tirzepatide, a once-weekly injection for type 2 diabetes, before Ramadan helps people manage their blood sugar safely while fasting. 166 adults with uncontrolled diabetes who planned to fast took part. Researchers measured changes in blood sugar levels, weight, and any side effects like low blood sugar or stomach issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

166 people

The number who actually took part.

Started

Oct 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a clinical diagnosis of uncontrolled Type 2 Diabetes based on the World Health Organization classification or other locally applicable diagnostic standards, and who intend to fast during Ramadan * Have HbA1c ≥7% within 30 days prior to screening * Are glucagon-like peptide-1 receptor agonist (GLP-1 RA) naïve * Have had stable body weight self-reported change ≤5 kilograms (kg) during the 90 days prior to screening * Have body mass index ≥25 kilograms per square meter (kg/m2) at screening Exclusion Criteria: * Have Type 1 Diabetes or gestational diabetes * Have a history of chronic or acute pancreatitis * Have acute or chronic hepatitis * Have evidence of a significant, uncontrolled endocrine abnormality * Have a history of an active or untreated malignancy * Have New York Heart Association Functional Classification IV congestive heart failure * Have been treated with insulin within two weeks prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fasting type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes

Contacts and locations

Locations

  • Al Dallah Hospital

    Riyadh, 11652, Saudi Arabia

  • Al Moosa Specialist Hospital

    Al Ahasa, 36342, Saudi Arabia

  • Aster Clinics

    Dubai, United Arab Emirates

  • Dallah Namar Hospital

    Riyadh, 14963, Saudi Arabia

  • Dr. Sulaiman Al Habib Hospital As Suwaidi

    Riyadh, 14963, Saudi Arabia

  • Dr. Sulaiman Al Habib Medical Complex Arrayan Saudi Arabia

    Riyadh, Saudi Arabia

  • Dubai Diabetes Center

    Dubai, United Arab Emirates

  • Dubai Hospital

    Dubai, United Arab Emirates

  • Emirates Hospital Dubai

    Dubai, 0000, United Arab Emirates

  • Imperial College London Diabetes Center

    Abu Dhabi, United Arab Emirates

  • King Abdulaziz Medical City-Jeddah

    Jeddah, 21423, Saudi Arabia

  • King Fahad Armed Forces Hospital Jeddah

    Jeddah, 21433, Saudi Arabia

  • King Faisal Specialist Hospital & Research Center

    Jeddah, 21499, Saudi Arabia

  • King Faisal Specialist Hospital and Research Center Madina

    Madinah, 42523, Saudi Arabia

  • King Saud University

    Riyadh, 11472, Saudi Arabia

  • Lifecare Hospital

    Abu Dhabi, 133500, United Arab Emirates

  • Medcare Hospital

    Dubai, United Arab Emirates

  • Medcare Hospital

    Sharjah city, 0000, United Arab Emirates

  • Mediclinic City Hospital

    Dubai, United Arab Emirates

  • NMC Abu Dhabi

    Abu Dhabi, United Arab Emirates

  • National Guard Hospital-King Abdulaziz Medical City

    Alahsa, 36428, Saudi Arabia

  • Osepdale Fatebenefratelli e Oftalmico

    Riyadh, 11525, Saudi Arabia

  • Rashid Centre for Diabetes and Research

    Ajman, United Arab Emirates

  • Rashid Hospital.

    Dubai, United Arab Emirates

  • Saudi Airlines Medical services

    Jeddah, Saudi Arabia

  • Specialized Medical Center Hospital

    Riyadh, 12311, Saudi Arabia

  • Sulaiman Habib Olaya

    Riyadh, 12214, Saudi Arabia

  • Tawam Hospital

    Abu Dhabi, 34761, United Arab Emirates

  • Thumbay University Hospital

    Ajman, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.